Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward E Cable

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Alimentary Pharmacology & Therapeutics|March 30, 2026
Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary CholangitisJörn M Schattenberg, Jesus M Banales, Gideon Hirschfield, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|June 20, 2020
The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in miceHuikuan Chu, Lu Jiang, Bei Gao, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 16, 2008
Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonistJames M Fujitaki, Edward E Cable, Bruce R Ito, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 20, 2007
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic indexMark D Erion, Edward E Cable, Bruce R Ito, et al.
PPAR Research|November 3, 2025
Single-Nuclei RNA Sequencing Shows the Engagement of PPAR-Delta Target Genes Primarily in Hepatocytes and Cholangiocytes by the Selective PPAR-Delta Agonist SeladelparTomoo Yamazaki, Yongqiang Yang, David Schöler, et al.
Journal of Medicinal Chemistry|November 4, 2008
Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugsSerge H Boyer, Hongjian Jiang, Jason D Jacintho, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
A Potent and Selective AMPK Activator That Inhibits de Novo LipogenesisJorge E Gómez-Galeno, Qun Dang, Thanh H Nguyen, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Alimentary Pharmacology & Therapeutics|March 30, 2026
Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary CholangitisJörn M Schattenberg, Jesus M Banales, Gideon Hirschfield, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|June 20, 2020
The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in miceHuikuan Chu, Lu Jiang, Bei Gao, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 16, 2008
Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonistJames M Fujitaki, Edward E Cable, Bruce R Ito, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 20, 2007
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic indexMark D Erion, Edward E Cable, Bruce R Ito, et al.
PPAR Research|November 3, 2025
Single-Nuclei RNA Sequencing Shows the Engagement of PPAR-Delta Target Genes Primarily in Hepatocytes and Cholangiocytes by the Selective PPAR-Delta Agonist SeladelparTomoo Yamazaki, Yongqiang Yang, David Schöler, et al.
Journal of Medicinal Chemistry|November 4, 2008
Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugsSerge H Boyer, Hongjian Jiang, Jason D Jacintho, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
A Potent and Selective AMPK Activator That Inhibits de Novo LipogenesisJorge E Gómez-Galeno, Qun Dang, Thanh H Nguyen, et al.
Pageof 2